Elevance Health (ELV) Q4 2025 earnings review
Revenue Grows, Profits Reset: The 2026 Trough
Elevance Health delivered a bittersweet Q4: Revenue surged 10% to $49.3B, but the bottom line buckled under the weight of medical costs. The Health Benefits segment swung to an operating loss of $200M as the Benefit Expense Ratio (BER) spiked to 93.5%. Consequently, management has reset expectations for FY26, guiding Adjusted EPS down ~16% to 'at least $25.50' (vs. $30.29 in FY25). While Carelon continues to grow revenue rapidly (+27%), it could not offset the profitability collapse in the core insurance business caused by Medicaid acuity mismatches and Medicare Part D seasonality.
🐂 Bull Case
The Carelon services arm is expanding aggressively, with revenue up 27% YoY to $18.7B. As the company diversifies away from pure-play health insurance, Carelon provides a hedge, though its margin profile is currently under pressure from mix shift.
By guiding FY26 earnings down significantly ($25.50 vs ~$30 prior), management effectively sets a 'floor' or trough year. If Medicaid rate adjustments catch up to acuity trends as planned, 2027 could see a sharp rebound.
🐻 Bear Case
The Health Benefits segment reported an Adjusted Operating Loss of $200M (vs. +$200M gain a year ago). A Benefit Expense Ratio of 93.5% indicates the company is currently underwriting policies at a loss in the quarter, driven by higher medical costs and Part D seasonality.
While Carelon revenue grew 27%, Adjusted Operating Gain was flat ($0.6B). Operating margins compressed from 4.4% to 3.3%, suggesting the 'growth' is coming from lower-margin product revenue rather than high-margin service efficiency.
⚖️ Verdict: 🔴
Bearish. The revenue growth is empty calories if margins continue to collapse. The swing to an operating loss in Health Benefits and the ~16% downward reset in FY26 earnings guidance signals structural headwinds (Medicaid/Part D) that will take at least 12-18 months to resolve.
Key Themes
Health Benefits Segment Swings to Loss
For the first time in recent trends, the Health Benefits segment posted an Adjusted Operating Loss of $200M in Q4, compared to a $200M gain in 24Q4. Despite raising premiums (driving revenue +11%), claims costs rose faster. This indicates a severe mismatch between pricing and actual medical acuity, particularly in Medicaid and Medicare Part D.
Benefit Expense Ratio (BER) Spike
The BER hit 93.5% in Q4, up 110 basis points YoY and significantly higher than the FY25 average of 90.0%. Management attributes this to 'heightened Medicare Part D seasonality driven by Inflation Reduction Act changes' and elevated medical cost trends in ACA plans. This level of medical expense leaves almost no room for operating overhead coverage.
Carelon Revenue Explosion vs. Margin Compression
Carelon is the growth engine, with Q4 revenue up 27% to $18.7B. However, this is 'empty' growth regarding profitability. Adjusted Operating Gain was flat at $0.6B YoY. Margins compressed to 3.3% from 4.4% YoY. This suggests the growth is driven by lower-margin pharmacy product revenue and the integration of CareBridge, rather than high-margin services.
Medicaid Membership Attrition
Medicaid membership dropped 4.7% YoY to 8.5 million members. This attrition is a double-edged sword: the company is losing revenue, but the remaining pool appears to be higher acuity (sicker), which is driving up the medical cost ratio. The 'redetermination' cycle is leaving Elevance with a more expensive risk pool that state rates have not yet matched.
Medicare Part D Seasonality Shift
The Inflation Reduction Act (IRA) has fundamentally altered the earnings seasonality. Q4 was hit hard by 'heightened Medicare Part D seasonality.' This structural change concentrates earnings in the first half of the year and creates significant pressure in Q4, contributing to the segment loss.
Capital Return Remains Active
Despite earnings pressure, Elevance returned $4.1B to shareholders in 2025 ($471M in buybacks in Q4). The company still has $6.7B in repurchase authorization remaining. However, with FY26 cash flow guidance lower than FY24 levels, the pace of buybacks may face scrutiny.
Other KPIs
Decelerating. Cash flow dropped significantly from $5.8B in FY24 (and $8.1B in FY23). Current OCF covers only 0.8x GAAP Net Income. This deterioration in cash conversion quality is a concern alongside falling earnings.
Decelerating. Down 1.1% YoY (loss of 0.5M members). Growth in Medicare Advantage (+7.9%) was insufficient to offset losses in Medicaid (-4.7%) and Commercial Risk-Based (-1.5%).
Stable. Decrease of 0.1 days vs Q3 and 1.9 days vs prior year. While a lower DCP can indicate faster payments, in an environment of rising medical costs, it creates a risk that reserves for 'Incurred But Not Reported' (IBNR) claims might be too thin.
Guidance
Reversing. Represents a ~16% decline from FY25's $30.29. This is a major reset, acknowledging that the cost headwinds (Medicaid/ACA) are structural and will persist through the year.
Accelerating. Implies a recovery from FY25's $4.3B, but remains well below the $8.0B+ levels seen in FY23. This suggests working capital headwinds will ease slightly but not resolve.
Reversing. Down ~11.5% from FY25 GAAP EPS of $25.21. The gap between GAAP and Adj EPS ($3.20) consists mostly of amortization and one-time costs.
Key Questions
Health Benefits Loss Structural vs. Seasonal
The Health Benefits segment swung to a $200M loss in Q4. How much of this is driven by the structural Part D seasonality changes from the IRA versus unexpected acuity spikes in Medicaid? Should we expect Q4 losses to be the new normal?
Carelon Margin Compression
Carelon revenue grew 27%, but operating income was flat, compressing margins by over 100bps. Is this purely mix shift from the CareBridge acquisition and pharmacy product growth, or is there underlying margin pressure in the core services business?
Confidence in 2027 Rebound
You reaffirmed the long-term algorithm of 12% growth for 2027. Given the 16% earnings drop guided for 2026, what specific rate adjustments or cost-of-care initiatives give you confidence that 2026 is truly the trough?
Cash Flow Deterioration
Operating cash flow has nearly halved from FY23 levels ($8.1B) to FY25 ($4.3B). What are the specific working capital headwinds driving this, and why should investors trust the guide for a bounce back to $5.5B in FY26?